Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7951 to 7965 of 8901 results

  1. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

    This guidance has been updated and replaced by NICE technology appraisal guidance 684.

    Withdrawn guidance

  2. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA872.

    Withdrawn guidance

  3. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

    This guidance has been updated and replaced by NICE technology appraisal guidance 692.  

    Withdrawn guidance

  4. Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 674. People already taking pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable through the Cancer Drugs Fund can continue. For those people, it will be funded by the company until they and their doctor decide when best to stop.

    Withdrawn guidance

  5. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)

    This guidance has been updated and replaced by NICE technology appraisal guidance 784.

    Withdrawn guidance

  6. Computerised cognitive behaviour therapy (CCBT) for the treatment of depression and anxiety (TA51)

    This guidance has been updated and replaced by NICE technology appraisal guidance 97.

    Withdrawn guidance

  7. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)

    This guidance has been updated and replaced by NICE technology appraisal guidance 783.

    Withdrawn guidance

  8. Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

    This guidance has been updated and replaced by NICE technology appraisal guidance 555.

    Withdrawn guidance

  9. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1021.

    Withdrawn guidance

  10. Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)

    This guidance has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  11. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA798.

    Withdrawn guidance

  12. Cenegermin for treating neurotrophic keratitis (TA532)

    We have withdrawn the guidance because cenegermin (Oxervate) is no longer available in the UK.

    Withdrawn guidance

  13. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

    This guidance has been updated and replaced by NICE guideline NG87.

    Withdrawn guidance

  14. Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)

    NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.

    Withdrawn guidance

  15. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (TA985)

    This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.

    Withdrawn guidance